Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Glycan therapeutic compositions and related methods thereof

Inactive Publication Date: 2018-05-31
DSM NUTRITIONAL PROD
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for using a glycan therapeutic composition to modulate the immune system and treat immune imbalances in a subject. The method can also include using an anti- or pro-inflammatory agent and a probiotic microorganism. The glycan therapeutic can affect the growth or activity of beneficial gut bacteria, such as Bifidobacteria, and can also modulate the growth or function of other bacterial species. The method can also involve modulating biomarkers and cytokines involved in inflammatory responses, such as interleukin-10, interleukin-4, and interleukin-13. The patent provides a technical solution for treating immune imbalances and nutritional imbalances in a subject.

Problems solved by technology

Maintaining or restoring human health faces a large number of challenges many of which result from the lack of effective treatment options.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glycan therapeutic compositions and related methods thereof
  • Glycan therapeutic compositions and related methods thereof
  • Glycan therapeutic compositions and related methods thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of Glycan Therapeutics

[0484]To a round bottom flask equipped with an overhead stirrer and a jacketed short-path condenser was added one or more mono- or disaccharides along with 3-20% by dry weight of one or more of the catalysts described in U.S. Pat. No. 8,466,242 and WO 2014 / 031956, which are incorporated herein by reference in their entirety. Water or another compatible solvent (1.54 equiv) was added to the dry mixture and the slurry was combined at approximately 100 rpm using a paddle sized to match the contours of the selected round bottom flask as closely as possible. The mixture was then heated to 80-155° C. Once the solids achieved a molten state, the vessel was placed under 10-1000 mbar vacuum pressure. The reaction was stirred for 30 minutes to 8 hours, constantly removing water from the reaction. Reaction progress was monitored by HPLC. When sufficient oligomerization had occurred, the stirrer was shut off, the reaction was cooled to room temperature and vented to atm...

example 2

ion of Glycan Therapeutics

[0491]Oligosaccharides synthesized as in Example 1 were dissolved in deionized water to a final concentration of 25-50 Brix. The material was then exposed to at least 2 mass equivalents of Dowex Monosphere 88 ion exchange resin. Exposure may occur by swirling in a flask at 120-170 rpm or by filtration through a wet slurry packed column as long as the residence time is sufficient for the solution to achieve a final pH between 3 and 5. The oligomer solution was isolated by filtration (as in the case of swirled reactions) or elution (as in the case of column filtration) and the process was repeated with Dowex Monosphere 77 ion exchange resin in an analogous fashion until the solution pH was above 5.5. Finally the solution was exposed to Dowex Optipore SD-2 Adsorbent decolorizing resin until the solution was sufficiently clarified and filtered through a 0.2 micron filter to remove residual resin and resin fines. The final solution was then concentrated to 50-85...

example 3

ion of Glycan Therapeutics by Removal of Low Molecular Weight Species

[0493]Oligomers prepared and purified as in Examples 1 and 2 were modified so as to remove low molecular weight species. The separation was achieved by osmotic separation. Approximately 45 cm of 1.0 kD MWCO Biotech CE dialysis tubing (31 mm flat width) from Spectrum Labs was placed into deionized water and soaked for 10 minutes, then one end was sealed with a dialysis tubing clip. A 25 Brix solution of 8 grams dry oligosaccharide was sterile filtered and sealed into the tube with a second clip along with a few mL of air to permit the tube to float. The filled tube was then placed in a 3 gallon tank of deionized water which was stirred with sufficient force to induce slow swirling of the sealed tubes. After 8 hours, the water in the tank was replaced and the tube was allowed to stir for an additional 16 hours. Once the dialysis was complete and the material had a DP2+ yield greater than 95% and a DP3+ yield greater ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said gycan therapeutics, e.g. in cancer therapy.

Description

CLAIM OF PRIORITY[0001]This application claims priority to U.S. Application No. 62 / 278,333, filed Jan. 13, 2016; U.S. Application No. 62 / 238,110, filed Oct. 6, 2015; U.S. Application No. 62 / 238,112, filed Oct. 6, 2015; U.S. Application No. 62 / 216,995, filed Sep. 10, 2015; U.S. Application No. 62 / 216,997, filed Sep. 10, 2015; U.S. Application No. 62 / 152,017, filed Apr. 23, 2015; U.S. Application No. 62 / 152,011, filed Apr. 23, 2015; and U.S. Application No. 62 / 152,007, filed Apr. 23, 2015. The disclosure of each of the foregoing applications is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Maintaining or restoring human health faces a large number of challenges many of which result from the lack of effective treatment options. There is a continued need for novel therapies and treatment regimens.SUMMARY OF THE INVENTION[0003]Provided herein are preparations of glycan therapeutics and pharmaceutical compositions, medical foods and dietary supplements ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/702A61P43/00A61K35/741A61P35/00A61P1/00A61P3/02A61K45/06A61P35/04A23L33/125A23L33/135
CPCA61K31/702A61P43/00A61K35/741A61P35/00A61P1/00A61P3/02A61K45/06A61P35/04A23L33/125A23L33/135A23V2002/00A23L33/21A61K31/715A61P37/02A61K2300/00A23V2200/324A23V2200/32A23V2200/308A23V2250/5116A23V2250/61A23V2250/608A23V2250/602A23V2250/618A23V2250/606A23V2250/638A61K31/716A61K31/733Y02A50/30
Inventor VON MALTZAHN, GEOFFREY A.YAMANAKA, YVONNE J.SILVERMAN, JAREDMILWID, JACKRUBENS, JACOB R.GEREMIA, JOHN M.
Owner DSM NUTRITIONAL PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com